Here’s what you should note:
1. Patient susceptibility to diseases as well as microbial agent’s nature and virulence are spurring market expansion.
2. Growing HAI prevalence, in tandem with a lack of awareness and insufficient training and infection control practices, is also fueling growth.
3. Additional factors leading to growth include:
• Inadequate healthcare infrastructure
• Low healthcare expenditures
• More chronic diseases with extended hospital stays
4. Microbial resistance growth and people using off-label antiseptics and drugs are driving market expansion.
5. In 2016, the market totaled $23.7 billion.
6. The report expects the market to increase at a 7.3 percent compound annual growth rate through 2022, hitting $36.16 billion.
More articles on quality and infection control:
Opioid abuse drops when providers check patients’ past prescriptions: 4 things to know
Nearly 22k US malaria-related hospitalizations reported in 14 years: 7 takeaways
AAFP submits physician-focused alternative payment model: 6 things to know
